Patent intelligence · RU
RU 2191009
METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RARalpha
METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RARalpha
Patent details — RU 2191009
- Jurisdiction
- RU
- Status
- expired
- Grant date
- Oct 20, 2002
- Expiration
- Oct 15, 2022
- Applicant
- ALLERGEN SEHJLZ INK [US]
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 19 A I, A61K 31/ 20 A I, A61K 31/ 27 A I
Quick answer
RU 2191009 (METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RARalpha) is held by ALLERGEN SEHJLZ INK [US]. Status: expired. Granted Oct 20, 2002. Expires Oct 15, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGEN SEHJLZ INK [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 19 A I, A61K 31/ 20 A I, A61K 31/ 27 A I, A61K 31/ 35 A I, A61K 31/ 38 A I
More from ALLERGEN SEHJLZ INK [US]
Related pharmaceutical patents in our USPTO index.
-
CN 112638413
Oral immunotherapy unit dose dispensing systems and methods
granted -
WO 2015187736
FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI
granted -
US 2014356438
PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS
granted -
US 2014271721
PEANUT FORMULATIONS AND USES THEREOF
granted -
US 2014271836
MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION
granted -
US 2013209398
CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE
granted -
CA 2849366
COMPOSITIONS ET PROCEDES POUR TRAITER LA PRESBYTIE, L'HYPERMETROPIE LEGERE ET L'ASTIGMATISME IRREGULIER
granted -
US 2012003230
SUSTAINED RELEASE DRUG DELIVERY SYSTEMS COMPRISING A WATER SOLUBLE THERAPEUTIC AGENT AND A RELEASE MODIFIER
granted
Frequently asked questions
What is US patent 2191009?
RU 2191009 (METHODS OF THERAPY BY APPLYING THE COMPOUNDS EITHER OF SPECIFIC OR SELECTIVE ACTIVITY TO RETINAL ACID RECEPTOR RARalpha) is held by ALLERGEN SEHJLZ INK [US]. Status: expired. Granted Oct 20, 2002. Expires Oct 15, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns RU 2191009?
ALLERGEN SEHJLZ INK [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does RU 2191009 expire?
Our index shows an expiration date of Oct 15, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.